BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 24674452)

  • 1. Detection of an activated JAK3 variant and a Xq26.3 microdeletion causing loss of PHF6 and miR-424 expression in myelodysplastic syndromes by combined targeted next generation sequencing and SNP array analysis.
    Kunze K; Gamerdinger U; Leßig-Owlanj J; Sorokina M; Brobeil A; Tur MK; Blau W; Burchardt A; Käbisch A; Schliesser G; Kiehl M; Rosenwald A; Rummel M; Grimminger F; Hain T; Chakraborty T; Bräuninger A; Gattenlöhner S
    Pathol Res Pract; 2014 Jun; 210(6):369-76. PubMed ID: 24674452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
    Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
    Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy.
    Gill H; Leung AY; Kwong YL
    Int J Mol Sci; 2016 Mar; 17(4):440. PubMed ID: 27023522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Small Noncoding RNAs Have Specific Expression Patterns in Plasma and Extracellular Vesicles in Myelodysplastic Syndromes and Are Predictive of Patient Outcome.
    Hrustincova A; Krejcik Z; Kundrat D; Szikszai K; Belickova M; Pecherkova P; Klema J; Vesela J; Hruba M; Cermak J; Hrdinova T; Krijt M; Valka J; Jonasova A; Merkerova MD
    Cells; 2020 Mar; 9(4):. PubMed ID: 32224889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myelodysplastic syndromes: molecular pathogenesis and genomic changes.
    Nolte F; Hofmann WK
    Ann Hematol; 2008 Oct; 87(10):777-95. PubMed ID: 18516602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations of myelodysplastic syndromes (MDS): An update.
    Ganguly BB; Kadam NN
    Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
    Jhanwar SC
    Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transfer RNA detection by small RNA deep sequencing and disease association with myelodysplastic syndromes.
    Guo Y; Bosompem A; Mohan S; Erdogan B; Ye F; Vickers KC; Sheng Q; Zhao S; Li CI; Su PF; Jagasia M; Strickland SA; Griffiths EA; Kim AS
    BMC Genomics; 2015 Sep; 16():727. PubMed ID: 26400237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
    Duncavage EJ; Tandon B
    Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic modeling study on the pathogenic role of p38 MAPK activation in myelodysplastic syndromes.
    Peng H; Wen J; Zhang L; Li H; Chang CC; Zu Y; Zhou X
    Mol Biosyst; 2012 Apr; 8(4):1366-74. PubMed ID: 22327869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired mutations in TET2 are common in myelodysplastic syndromes.
    Langemeijer SM; Kuiper RP; Berends M; Knops R; Aslanyan MG; Massop M; Stevens-Linders E; van Hoogen P; van Kessel AG; Raymakers RA; Kamping EJ; Verhoef GE; Verburgh E; Hagemeijer A; Vandenberghe P; de Witte T; van der Reijden BA; Jansen JH
    Nat Genet; 2009 Jul; 41(7):838-42. PubMed ID: 19483684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent exome-targeted next-generation sequencing and single nucleotide polymorphism array to identify the causative genetic aberrations of isolated Mayer-Rokitansky-Küster-Hauser syndrome.
    Chen MJ; Wei SY; Yang WS; Wu TT; Li HY; Ho HN; Yang YS; Chen PL
    Hum Reprod; 2015 Jul; 30(7):1732-42. PubMed ID: 25924657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis.
    McGraw KL; Cheng CH; Chen YA; Hou HA; Nilsson B; Genovese G; Cluzeau T; Pellagatti A; Przychodzen BP; Mallo M; Arenillas L; Mohamedali A; Adès L; Sallman DA; Padron E; Sokol L; Moreilhon C; Raynaud S; Tien HF; Boultwood J; Ebert BL; Sole F; Fenaux P; Mufti GJ; Maciejewski JP; Kanetsky PA; List AF
    Blood Adv; 2019 Nov; 3(22):3579-3589. PubMed ID: 31738830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.
    Zhang L; Padron E; Lancet J
    Leuk Res; 2015 Jan; 39(1):6-17. PubMed ID: 25465125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single nucleotide polymorphism array karyotyping: a diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing.
    Arenillas L; Mallo M; Ramos F; Guinta K; Barragán E; Lumbreras E; Larráyoz MJ; De Paz R; Tormo M; Abáigar M; Pedro C; Cervera J; Such E; José Calasanz M; Díez-Campelo M; Sanz GF; Hernández JM; Luño E; Saumell S; Maciejewski J; Florensa L; Solé F
    Genes Chromosomes Cancer; 2013 Dec; 52(12):1167-77. PubMed ID: 24123380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Myelodysplastic syndromes].
    Thol F; Heuser M; Ganser A
    Internist (Berl); 2015 Apr; 56(4):364-73. PubMed ID: 25700647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations.
    Lai JL; Preudhomme C; Zandecki M; Flactif M; Vanrumbeke M; Lepelley P; Wattel E; Fenaux P
    Leukemia; 1995 Mar; 9(3):370-81. PubMed ID: 7885035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comprehensive analysis of genomic detection for a patient with myelodysplastic syndrome].
    Luo JX; Ai C; Huang YS; Wang HW; Hu CM; Zhao WW
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1501-6. PubMed ID: 24370037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
    Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
    Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.